Format

Send to

Choose Destination
Cancer Metastasis Rev. 2017 Sep;36(3):475-489. doi: 10.1007/s10555-017-9694-9.

Checkpoint immunotherapy in head and neck cancers.

Author information

1
Department of Otolaryngology, Washington University School of Medicine, St. Louis, MO, USA.
2
Brigham and Women's Hospital and Dana-Farber Cancer Institute, 45 Francis Street, Boston, MA, 02215, USA. ruppaluri@partners.org.

Abstract

Checkpoint inhibitors have recently gained FDA approval for the treatment of cisplatin-resistant recurrent and metastatic head and neck squamous cell carcinoma (HNSCC) by outperforming standard of care chemotherapy and inducing durable responses in a subset of patients. These monoclonal antibodies unleash the patient's own immune system to target cancer cells. HNSCC is a good target for these agents as there is ample evidence of active immunosurveillance in the head and neck and a number of immune evasion mechanisms by which HNSCCs form progressive disease including via the PD-1/PD-L1 axis. As HNSCCs typically possess a moderately high mutation burden, they should express numerous mutation-derived antigen targets for immune detection. However, with response rates less than 20% in clinical trials, there is a need for biomarkers to screen patients as well as clinical trials evaluating novel combinations to improve outcomes. The aim of this review is to provide historical and mechanistic context for the use of checkpoint inhibitors in head and neck cancer and provide a perspective on the role of novel checkpoints, biomarkers, and combination therapies that are evolving in the near term for patients with HNSCC.

KEYWORDS:

Checkpoint blockade; Head and neck squamous cell carcinoma; Immunotherapy

PMID:
28836124
DOI:
10.1007/s10555-017-9694-9
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center